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INTRODUCTION
The present desk study has been initiated by the Global Water Research Coalition (GWRC) to consolidate a uniform selection of compounds in order to judge risks of PhACs for the water cycle. The approach used, rather than embarking upon a new priority setting effort, was to identify some major existing prioritization efforts in North America, Europe, Australia and East Asia, and evaluate criteria used in those prioritization exercises. The study will thus yield a representative and qualitative profile ('umbrella view') of priority pharmaceuticals based on an extensive set of criteria. The list of representative priority PhACs can be used for further studies on analytical methods, occurrence, treatability, and potential risks associated with exposure to PhACs in the water supply. The list will identify compounds that are most likely to be encountered in water supplies and that may have significant impact on human health. For practical reasons, the present study excludes veterinary drugs. Once the draft final list has been established, its use within the GWRC membership will ensure that research findings are reliable and comparable. doi: 10.2166/wst.2009.764 METHODOLOGY Documentation from ongoing pharmaceuticals-prioritization activities were collected and additional information was submitted by a so called e-mail support group of experts related to the GWRC. It should be noted that the present study did not involve any new individual scoring of pharmaceuticals on particular criteria, as it made use of existing ranking documents only. Additional key references from the scientific literature were selected and screened for further underpinning of poorly represented criteria in the prioritization exercises. A total of 25 reports and references were used which had the prioritization of pharmaceuticals as key subject. The number of appearances of pharmaceuticals in the 25 base documents was scored.
Furthermore a list of criteria was established that gathered the criteria applied in the 25 base documents for selection or prioritization of pharmaceuticals. In total 17 different criteria were identified, most of them being used in several documents. The criteria employed in the base documents were subjected to expert judgement and evaluation by the project team members. Based on this judgement, seven criteria were regarded as being of special relevance for the GWRC members and selected as a basis for drawing up a second priority list. Subsequently, the initial list of pharmaceuticals (which was established by applying all criteria) was re-evaluated based on the selected seven criteria. Documents from the base set that did not use any of the final set of criteria were omitted and pharmaceuticals that did not score on these final criteria were deleted from the initial list. Finally the chemicals were ranked based on the number of fulfilled criteria. The approach is illustrated in Figure 1 .
RESULTS AND CONCLUSIONS

Base documents
Twenty-five documents served as the base documents for this study. The documents are presented in the list of references. By using these twenty-five documents it was tried to cover the different approaches used in various countries (with special emphasis on countries represented within the GWRC) and by groups with different objectives and background. Although this set of base documents is not exhaustive, it represents an 'average' of approaches used in various countries and provides a good overview of criteria used in priority setting of pharmaceuticals.
A total of 153 pharmaceuticals were listed in the base documents. Twenty-four of these occurred in two priority lists, 16 pharmaceuticals appeared in 3 to 5 lists, and 19 appeared in more than 5 lists.
Rationale for criteria selection
The criteria used in the base documents are tabulated in Table 1 . In total 17 criteria were mentioned in all base documents together. From these, seven criteria were selected for use in a second step (see Figure 1 ). Only scientific considerations were used for selection of criteria and especially those criteria were selected that were regarded as being of particular relevance for the GWRC members. The rationale for selection of criteria is also given in Table 1 .
Apart from the criteria used in the base documents, public interest and media coverage were discussed as other possible criteria (e.g. referring to HIV treatment, hard drugs, Viagra).
From a scientific point of view, these criteria were judged as of less importance than the seven selected and thus no longer used for further evaluation. No further prioritization of the criteria selected was made, i.e. all seven criteria were considered as being equally important.
In addition to the selection of pharmaceuticals from the initial list according to the seven criteria, the antibacterial triclosan and the natural hormones 17ß-estradiol and Table 2 .
Obviously, the more a pharmaceutical is cited in priority lists, the more likely it will have been evaluated 
Classification
Based on the scorings outlined above, different lists can be made, categorizing the pharmaceuticals in several classes: Occurrence of a compound in the environment is one of the key criteria for its selection because if a compound is found in the environment there is a need for further activities (e.g. evaluation of its relevance or behaviour during treatment). At this stage, the different types of waters (wastewater, surface water, groundwater, drinking water,…) will not be weighted. However, if a compound is only found in the influent of a wastewater treatment plant but not in the effluent and not in other types of waters it will be regarded as less relevant The numbers do not correspond to any priority ranking. 
Class 1: high priority pharmaceuticals
Pharmaceuticals that are mentioned in five or more of the base documents cited, and that fulfil more than four of the seven criteria
Class 2: priority pharmaceuticals
Pharmaceuticals that are mentioned in more than two of the base documents cited, and that fulfil more than two criteria. Class 3: lower priority pharmaceuticals
Pharmaceuticals that are mentioned in two documents of the base documents cited, and fulfil two or more criteria
The three classes are presented in Tables 3, 4 and 5, respectively, together with the citation frequencies and number and type of criteria relevant.
CONCLUSIONS
A short list of 10 compounds was extracted from the literature review work on prioritisation. These compounds represent the minimum that should be considered in any study on pharmaceuticals in water management. Lists II and III represent secondary targets, but nevertheless include several pharmaceuticals that are well known from many monitoring studies. Which lists are to be used in further research, will depend on the goal of the individual research projects.
The lists derived in this study are only based on compounds already mentioned in the literature. As a consequence they will be time related. This means that this list will need to be updated depending on the outcomes of future studies (especially given the increasing occurrence dataset). Attention for 'new' compounds therefore will remain relevant.
In the current study equal weight was given to all criteria selected. It can be discussed whether certain criteria should have more weight or not. This might results in small changes between the lists, but it is expected that the current lists still give a good view of the relevant compounds.
Despite those limitations, which are inherent to this type of exercise, the pragmatic approach that has been adopted in this work provides an efficient tool to manage the risks related to pharmaceuticals in the drinking water industry.
This report provides assistance for selecting pharmaceuticals for future studies. It will enable harmonization of the selection of compounds to be studied and thereby contribute to comparability of results worldwide.
